AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 277: H1260-H1264, 1999;
0363-6135/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katovich, M. J.
Right arrow Articles by Raizada, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katovich, M. J.
Right arrow Articles by Raizada, M. K.
Vol. 277, Issue 3, H1260-H1264, September 1999

RAPID COMMUNICATION
Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR

Michael J. Katovich1, Craig H. Gelband2, Phyllis Reaves2, Hong-Wei Wang2, and Mohan K. Raizada2

1 Department of Pharmacodynamics, College of Pharmacy, and 2 Department of Physiology, College of Medicine, University of Florida, Gainesville, Florida 32610

Pharmacological blockade of the renin-angiotensin system in both hypertensive patients and animal models such as the spontaneously hypertensive rat (SHR) effectively reduces blood pressure (BP). Recent studies have established that virally mediated delivery (vector LNSV) of antisense to the angiotensin II type 1 receptor (LNSV-AT1R-AS) will attenuate or abolish the development of hypertension in the SHR. However, the effectiveness of this gene therapy approach to reduce high BP once it is established in the adult has not been ascertained. In this study, we investigated the hypothesis that viral delivery of AT1R-AS into the adult SHR will reduce BP and reverse the vascular reactivity associated with the hypertension. Intracardiac injection of virus particles containing LNSV-AT1R-AS into adult SHR resulted in a 30- to 60-mmHg reduction in BP that was maintained for up to 36 days compared with SHR treated with virus alone (LNSV without antisense). Measurement of renal resistance arteriolar reactivity demonstrated a leftward shift in the KCl and phenylephrine concentration-response relationships and an impaired endothelium-dependent relaxation to ACh in LNSV-treated SHR compared with control Wistar-Kyoto rats. These vascular alterations were reversed in the LNSV-AT1R-AS-treated SHR. Collectively, these data demonstrate that virally mediated gene delivery of AT1R-AS can effectively reduce BP and reverse renovascular pathophysiology associated with the hypertensive state when administered to the adult SHR.

renovascular responsiveness; blood pressure


This article has been cited by other articles:


Home page
 HypertensionHome page
B. Kimura, D. Mohuczy, X. Tang, and M. I. Phillips
Attenuation of Hypertension and Heart Hypertrophy by Adeno-Associated Virus Delivering Angiotensinogen Antisense
Hypertension, February 1, 2001; 37(2): 376 - 380.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. S. Pachori, H. Wang, C. H. Gelband, C. M. Ferrario, M. J. Katovich, and M. K. Raizada
Inability to Induce Hypertension in Normotensive Rat Expressing AT1 Receptor Antisense
Circ. Res., June 9, 2000; 86(11): 1167 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
P. Y. Reaves, C. H. Gelband, H. Wang, H. Yang, D. Lu, K. H. Berecek, M. J. Katovich, and M. K. Raizada
Permanent Cardiovascular Protection From Hypertension by the AT1 Receptor Antisense Gene Therapy in Hypertensive Rat Offspring
Circ. Res., November 12, 1999; 85 (10): e44 - e50.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online